Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 8/20 | 0.35 |
| ▸ | IGF1R | P08069 | 3/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226580 | 0.89 | PLK1 (0.38) | PLK1IDH1IGF1RCDK2CDK1 | |
| SCHEMBL3550470 | 0.88 | IDH1 (0.41) | PLK1IDH1IGF1RCDK2CDK1 | |
| SCHEMBL2195522 | 0.85 | PLK1 (0.39) | PLK1IDH1IGF1RCDK2CDK1 | |
| SCHEMBL2198081 | 0.85 | PLK1 (0.38) | PLK1IDH1IGF1RCDK2FLT3 | |
| SCHEMBL2227194 | 0.85 | TYRO3 (0.39) | PLK1IDH1IGF1RCDK2 | |
| SCHEMBL2199778 | 0.85 | PLK1 (0.38) | PLK1IDH1IGF1RKCNJ1CDK2 | |
| SCHEMBL2197910 | 0.84 | PLK1 (0.38) | PLK1GAAIDH1IGF1RCDK2 | |
| SCHEMBL2199108 | 0.84 | PLK1 (0.34) | PLK1IDH1IGF1RCDK2CDK1 | |
| SCHEMBL4272407 | 0.84 | PLK1 (0.34) | PLK1IDH1IGF1RCDK2CDK1 | |
| SCHEMBL2196563 | 0.84 | PLK1 (0.34) | PLK1IDH1IGF1RCDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | PLK1 1/4885GAA 4465/4885IDH1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.